

FINAL Comprehensive Research Plan:

Treatment of Attention Deficit Hyperactivity Disorder in Adults

Environmental Scan

April 27th, 2015

ODPRN Drug Class Review Proposal: Environmental Scan

Study Title: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults

Objectives:

1. To summarize the pharmacy benefit programs for drugs for treatment of ADHD (stimulants and non-stimulants) in Ontario, across Canada and in select international jurisdictions
 2. To determine the impact of different drug reimbursement schemes for drugs for treatment of ADHD (stimulants and non-stimulants) on patient access, quality of life and/or utilization and costs
 3. To summarize the guidelines for management of adult patients with ADHD
-

Study Questions:

In adult patients with ADHD:

1. How are treatment options (stimulants and non-stimulants) currently being accessed in publicly funded programs across Canada as well as internationally?
2. What is the impact of different drug reimbursement schemes for stimulants and non-stimulants on patient access, quality of life and/or utilization and costs?
3. Does sex, gender or socioeconomic status play an important role in any of the analyses described?

Objective 1: Pharmacy Benefit Programs in Ontario, across Canada and internationally

Study Design:

Design: summary of available information available through the Internet; interviews with individuals at the government agencies responsible for the public drug plan

Data sources: Internet, direct contact with individuals

Study Population:

- Canada: provincial/territorial public plans
- England, Wales, Northern Ireland, Scotland: NICE (National Institute for Health and Care Excellence)
- Australia: Pharmaceutical Benefits Scheme
- United States: Medicare, Veterans Affairs
- New Zealand: PHARMAC (Pharmaceutical Management Agency)

Intervention:

- Stimulants (amphetamine mixture, dextroamphetamine, lis-dexamfetamine, methylphenidate)
- Non-stimulants (atomoxetine, guanfacine)

Outcome(s) of Interest:

Drug Reimbursement Criteria and Policies:

- Restricted Access vs. General Benefit
- Specific restriction criteria

Objective 2: Impact of different drug reimbursement schemes for drugs for treatment of ADHD

Study Design: Design: Literature review
Data sources: Medline, EMBASE, Cochrane Collection, Grey literature

Study Population: Stimulants and non-stimulants for treatment of ADHD

Intervention: Various drug reimbursement schemes, including general benefits, step therapy, special authorization

Outcome(s) of Interest: Indirect/direct measurements of clinical outcomes, patient satisfaction, quality of life, utilization and/or costs, functionality at work, days of productivity at work

Objective 3: Guidelines for use of stimulants and non-stimulants for treatment of ADHD in adults

Study Design: Design: Literature review
Data sources: Medline, EMBASE, Cochrane Collection, Grey literature

Study Population: Stimulants and non-stimulants for treatment of ADHD in adults

Intervention: Guidelines/recommendations for the use of stimulants and non-stimulants for treatment of ADHD in adults

Outcome(s) of Interest: Published guidelines by various organizations: CADDRA (2011), NICE (2008)